A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is: evaluate the safety and activity of administering arsenic
trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to
evaluate the qualitative and quantitative toxicities of this treatment, and to measure the
response to treatment and the patterns of failure and survival. The primary response
measurements will be the achievement of an objective tumor response, response duration and
progression-free survival